Safety and Activity of the Once Daily Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701 in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma

Drug Category: Array
Conference Category: Array
Lead Author: Cheah C, et al.
Published Date: 12/06/2020
Download Link: /wp-content/uploads/2020/06/Final-EHA-TG-1701-Phase-1-Poster.pdf
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top